The study involving 1,119 participants will be published in Cell Reports Medicine.

Currently, genetic testing is divided into three distinct approaches:

In a new study, scientists have developed a more precise genetic risk score to determine whether a person is likely to develop arrhythmia, an irregular heartbeat that can lead to serious conditions such as atrial fibrillation (AFib) or sudden cardiac death.

Their approach not only improves the accuracy of heart disease risk prediction but also offers a comprehensive framework for genetic testing that, according to the scientists, could be applied to anything, including other complex, genetically influenced diseases like cancer, Parkinson’s Disease and autism.

“It’s a very cool approach in which we are combining rare gene variants with common gene variants and then adding in non-coding genome information. To our knowledge, no one has used this comprehensive approach before, so it’s really a roadmap of how to do that,” said co-corresponding author.

Alzheimer’s disease (AD) is a neurodegenerative condition characterized by the progressive deterioration of brain cells, which prompts memory loss, a decline in mental functions and behavioral changes. Estimates suggest that this disease affects approximately 1 in 14 people who are more than 65 years old and over 35% of people who are over 85 years old.

Due to its prevalence and debilitating nature, AD has become the focus of numerous neuroscience and medical studies. Most of these studies examined brain regions and neurogenetic processes that appear to be different in people diagnosed with AD.

Recently, some neuroscientists gathered evidence suggesting that parts of the brain that support somatosensory processing (i.e., the interpretation of tactile stimuli, pressure and the body’s position in space), are also affected in individuals with AD. Yet the extent to which these tactile sensation-related deficits play a role in the cognitive decline typical of AD has not yet been determined.